Todos Medical Ltd revealed that the first commercial patient samples have been received for its Long COVID Panel biomarker partnership between its CLIA/CAP certified lab Provista Diagnostics and Amerimmune Diagnostics, which also has a CLIA/CAP certified lab with immune diagnostics expertise.
The medical diagnostics company said the patient samples were requisitioned by Long COVID clinic Real Time Health Monitoring (RTHM). Todos said they were collected at a Quest Diagnostics (NYSE:DGX) center in the US and shipped to Amerimmune’s lab in McLean, Virginia for processing.
The cPass neutralizing antibody and total antibody portion of the panel is being subcontracted to Provista in Atlanta and the data sent back to Amerimmune to include in their report back to the RTHM physician, noted the company. Significantly, the biomarker tests included in the Long COVID Panel are covered by commercial insurance and Medicare.
READ: Todos Medical partners with Amerimmune Diagnostics on long-COVID biomarker panel
In addition, RTHM physicians are now working with Todos' subsidiary 3CL Pharma on its Tollovid 3CL protease inhibitor immune support supplement case study series and will now begin to monitor biomarker data with the Long COVID Panel. The objective is for Long COVID Panel data to be included in Todos' ongoing Tollovid case study series going forward to corroborate perceived patient benefits.
Todos intends to use data gathered during the case study series and its ongoing IRB-waived market research study to inform Tollovid dosing recommendations for clients. Moreover, Todos is planning a controlled Tollovid Phase 2 study.
"We are really pleased to see the pieces coming together to allow for our evaluation of Tollovid as a potentially important supplement for Long COVID," RTHM Chief Medical Officer Dr Jennifer Curtin said in a statement.
"We’ve had patients who have experienced tremendous results on Tollovid and others who did not benefit as much. We are now looking to expand our evaluation of immune biomarkers in Long COVID to better understand which patients may benefit from Tollovid alone, or potentially in combination with other products…This is critical for Long COVID patients to understand so that we can develop individualized regimens to give each patient that best opportunity for healing," she added.
Tollovid is a patent-protected dietary supplement, which is a proprietary blend of plant extracts that include a 3CL protease inhibitor that could help support healthy immune function.
Founded in Rehovot, Israel with offices in New York City, Todos also engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter (NYSE:TWTR): @UttaraProactive